Ranked #1 Children's Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
Megaloblastic anemia, also known as pernicious anemia, is a type of anemia characterized by very large red blood cells.
In addition to the cells being large, the inner contents of each cell are not completely developed; this malformation causes the bone marrow to produce fewer cells, and sometimes the cells die earlier than the 120-day life expectancy.
Patients with Megaloblastic pernicious anemia are treated at Dana-Farber/Boston Children's Cancer and Blood Disorders Center through the Blood Disorders Center, an integrated pediatric hematology and oncology partnership between Dana-Farber Cancer Institute and Boston Children’s Hospital.
How Dana-Farber/Boston Children's approaches megaloblastic anemia
The Clinical Nutrition Service (CNS) provides comprehensive nutrition consultation services for patients of all ages in both the inpatient and outpatient settings. Using innovative diagnostic and evaluation techniques, our staff develops appropriate nutrition plans for infants, children and adolescents who suffer from a variety of disorders.
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”